Collaboration Aims To Identify Optimized Antibodies for Novel Cancer Targets
Complete the form below to unlock access to ALL audio articles.
IONTAS, a company focused on the discovery and optimization of fully human antibodies, has announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The agreement is to generate and optimize antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties.
IONTAS’ proprietary technology enables the construction of large libraries of stable cell lines displaying human antibodies on their surface. As well as generating therapeutic antibody leads, the technology also aims to address “developability” issues early in discovery; increasing the likelihood of successful progress through the development process. Under the terms of the collaboration, the project provides Adaptate Biotherapeutics with access to IONTAS’ proprietary Mammalian Display technology, allowing the selection of high-affinity antibodies based on their function, stability, expression and developability thereby facilitating a speedy transition through Chemistry, Manufacturing and Controls (CMC) and eventual manufacturing.